Piramal Pharma Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Piramal Pharma (NSE: PPLPHARMA) is preparing to announce its Q4 FY26 financial results for the quarter ended March 31, 2026. With Piramal Pharma trading at Rs 182 — against a 52-week high of Rs 268 and a 1-year return of -20% — the Q4 FY26 results will be a pivotal event for investors tracking the Pharma/CDMO sector.

Analyst estimates for Q4 FY26 revenue stand at Rs 2,400–2,600 Cr, with PAT expectations of Rs 28–55 Cr and margin projections of EBITDA 16–19%. This article covers the Piramal Pharma Q4 results 2026 date, detailed earnings estimates, five key performance factors, five risks to monitor, analyst ratings, and answers to the most commonly searched investor questions.

Get free investment predictions on Univest.

Piramal Pharma Q4 Results 2026 Date

Piramal Pharma has scheduled its Q4 FY26 results for May 2026 (Expected). The board of directors will meet to approve audited financial statements for the quarter ended March 31, 2026, and to consider a final dividend recommendation. At a CMP of Rs 182, investors will closely watch this announcement for revenue growth confirmation and FY27 guidance.

Why This Quarter Matters

Q4 FY26 is the final quarter of the financial year — it determines full-year FY26 performance, sets the FY27 estimate base, and triggers final dividend announcements. For Piramal Pharma, operating in the Pharma/CDMO sector, Q4 will reveal whether earlier-quarter momentum has sustained and whether management’s strategic initiatives are delivering measurable financial outcomes.

At a 1-year return of -20%, the Q4 FY26 results and FY27 guidance commentary will be critical in determining whether the stock can recover toward its 52-week high of Rs 268. Investors will focus on order book updates, margin trajectory, and management tone — positive surprises on multiple parameters could drive a meaningful re-rating.

Piramal Pharma Q4 FY26 Earnings Estimates

Access premium SEBI-registered research on Univest.

Analysts covering Piramal Pharma have published Q4 FY26 estimates reflecting sector trends and company-specific catalysts. Consensus points to revenue of Rs 2,400–2,600 Cr, PAT of Rs 28–55 Cr, and margins of EBITDA 16–19%. These projections incorporate Q4 seasonal strength and ongoing business improvements.

Beyond headline numbers, investors should monitor FY27 guidance commentary, working capital trends, and order book visibility. A clean recurring profit print — rather than one inflated by non-operational items — carries greater weight with long-term investors.

Screen Piramal Pharma fundamentals on Univest Screener.

5 Key Factors That Will Drive Piramal Pharma Q4 FY26 Performance

CDMO Revenue Acceleration

Piramal Pharma’s CDMO business — serving global innovator pharma companies with contract manufacturing of complex molecules — is the highest-growth and highest-margin segment. Q4 FY26 CDMO revenue growth of 15–20% YoY would demonstrate that global pharma outsourcing trends are driving demand for Piramal’s specialised capabilities in complex chemistry.

Complex Hospital Generics (CHG) Improvement

The CHG segment — hospital sterile injectables and anaesthesia products sold in the US and Europe — has been recovering after prior-year execution challenges. Q4 FY26 CHG revenue growth and gross margin improvement would signal that operational issues have been resolved and the segment is back on a growth trajectory.

India Consumer Healthcare Revenue

Piramal’s India consumer healthcare business — selling OTC brands like Lacto Calamine, Little’s, and Littles Care — provides steady domestic revenue. Q4 FY26 will reflect summer-season demand for skin care and baby care products. Growth in this segment supports the overall revenue diversification story.

PAT Recovery to Positive

Piramal Pharma reported a Q3 FY26 net loss of Rs 18 Cr. Q4 FY26 is expected to see a return to PAT positive — driven by CDMO revenue growth, CHG operational improvement, and absence of exceptional items. A positive PAT print of Rs 30–55 Cr would be the single most important result for investor sentiment.

Debt Reduction and Financial Health

Piramal Pharma carries significant debt from its CDMO capacity expansion. Q4 FY26 will reflect free cash flow generation and progress on debt reduction. Any improvement in net debt levels — driven by CDMO contract milestones and CHG recoveries — would reduce financial risk and improve credit ratings.

5 Risks to Watch in Piramal Pharma Q4 FY26

CDMO Execution and Capacity Utilisation

CDMO revenues depend on successfully commissioning new capacity and achieving regulatory approvals for manufacturing sites. Any delays in US FDA approvals or utilisation ramp-up would disappoint CDMO revenue estimates.

CHG Price Pressure in Sterile Injectables

The US hospital sterile injectable market is competitive. Price erosion in CHG products could offset volume growth and compress margins despite revenue growth.

Regulatory Risk — US FDA

Piramal’s manufacturing facilities are subject to US FDA inspections. Any import alert or warning letter would halt exports to the US market, significantly impacting CDMO and CHG revenues.

High Debt Levels

Piramal Pharma’s elevated debt levels generate significant interest expenses. Until EBITDA grows sufficiently to comfortably cover debt service, financial risk remains elevated.

India Consumer Healthcare Competition

The OTC consumer healthcare market is highly competitive with Dabur, Himalaya, and global FMCG players. Market share pressure in India consumer brands could limit the segment’s growth contribution.

Piramal Pharma Share Price and Analyst Ratings

Piramal Pharma is trading at Rs 182 as of early April 2026, against a 52-week high of Rs 268 and 52-week low of Rs 142. Market cap stands at Rs 12,850 Cr. The 1-year return of -20% reflects sector headwinds alongside company-specific factors. Analyst price targets range from the conservative to the optimistic, reflecting differing views on recovery pace and FY27 earnings potential.

Download the Univest iOS App or Univest Android App to track Piramal Pharma’s live price and receive real-time Q4 result alerts.

Conclusion

Piramal Pharma Q4 FY26 results will mark a critical milestone — the company’s return to profitability after a challenging FY26. At Rs 182, the stock is 32% below its 52-week high. PAT above Rs 40 Cr combined with CDMO revenue acceleration would be the strongest possible result to trigger a re-rating. US FDA inspection outcomes and CHG margin improvement are the key operational watchpoints. Consult a SEBI-registered advisor before investing.

This content is published by Univest, a SEBI-registered research and advisory platform. All analyst estimates and price targets cited are from publicly available broker notes. Past performance is not indicative of future results. Investors should conduct independent due diligence before making any investment decisions.

For more Q4 FY26 previews visit Univest Blogs.

Frequently Asked Questions

What is the Piramal Pharma Q4 results 2026 date?

Piramal Pharma Q4 FY26 results are scheduled for May 2026 (Expected). The board will meet to approve audited financial statements for the quarter ended March 31, 2026.

What is the Piramal Pharma Q4 FY26 PAT estimate?

Analysts estimate Piramal Pharma Q4 FY26 PAT in the range of Rs 28–55 Cr, on revenue of Rs 2,400–2,600 Cr and margin of EBITDA 16–19%. Actual results may differ from these estimates.

What is Piramal Pharma’s share price ahead of Q4 results?

Piramal Pharma shares are trading at approximately Rs 182 as of early April 2026. The 52-week high is Rs 268 and 52-week low is Rs 142. The one-year return is -20% and market cap stands at Rs 12,850 Cr.

Will Piramal Pharma declare a dividend in Q4 2026?

Piramal Pharma is expected to consider Nil expected at the Q4 FY26 board meeting on May 2026 (Expected). The dividend decision reflects management’s confidence in FY26 free cash flow generation.

Which analysts have a Buy rating on Piramal Pharma?

MOFSL (target Rs 230), Kotak Inst. (target Rs 225), Emkay (target Rs 218) ahead of Q4 FY26 results.

What were Piramal Pharma Q3 FY26 results?

In Q3 FY26, Piramal Pharma reported revenue of Rs 2,204 Cr and PAT of Rs -18 Cr with margins at EBITDA 15.2%. These provided the base for Q4 FY26 analyst estimates.

When do Infosys and TCS announce Q4 results 2026?

TCS announced Q4 FY26 results on April 9, 2026 — full preview at TCS Q4 Results 2026. Infosys announced results on April 23, 2026.

Is Piramal Pharma a good investment ahead of Q4 results?

Piramal Pharma at Rs 182 offers a risk-reward contingent on Q4 execution and FY27 guidance. Investors should review analyst estimates, monitor the results announcement, and consult a SEBI-registered advisor before making investment decisions.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings and company investor relations pages. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

Recent Article

Natural Capsules Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

National Fertilizers Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

National Aluminium Company Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook

Nath Bio-Genes (India) Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Narmada Agrobase Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook